These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 24523450)
1. Editorial on "targeting Wee1 for the treatment of pediatric high-grade gliomas". Chakravarti A Neuro Oncol; 2014 Mar; 16(3):325. PubMed ID: 24523450 [No Abstract] [Full Text] [Related]
2. Targeting Wee1 for the treatment of pediatric high-grade gliomas. Mueller S; Hashizume R; Yang X; Kolkowitz I; Olow AK; Phillips J; Smirnov I; Tom MW; Prados MD; James CD; Berger MS; Gupta N; Haas-Kogan DA Neuro Oncol; 2014 Mar; 16(3):352-60. PubMed ID: 24305702 [TBL] [Abstract][Full Text] [Related]
3. Strategies for Targeted Therapy in Head and Neck Squamous Cell Carcinoma Using WEE1 Inhibitor AZD1775. Kao M; Green C; Sidorova J; Méndez E JAMA Otolaryngol Head Neck Surg; 2017 Jun; 143(6):631-633. PubMed ID: 28208168 [TBL] [Abstract][Full Text] [Related]
4. Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs. Indovina P; Giordano A Cancer Biol Ther; 2010 Apr; 9(7):523-5. PubMed ID: 20150761 [No Abstract] [Full Text] [Related]
5. Wee1 kinase as a target for cancer therapy. Do K; Doroshow JH; Kummar S Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427 [TBL] [Abstract][Full Text] [Related]
6. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Sarcar B; Kahali S; Prabhu AH; Shumway SD; Xu Y; Demuth T; Chinnaiyan P Mol Cancer Ther; 2011 Dec; 10(12):2405-14. PubMed ID: 21992793 [TBL] [Abstract][Full Text] [Related]
7. An aqueous normal-phase chromatography coupled with tandem mass spectrometry method for determining unbound brain-to-plasma concentration ratio of AZD1775, a Wee1 kinase inhibitor, in patients with glioblastoma. Wu J; Sanai N; Bao X; LoRusso P; Li J J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():25-32. PubMed ID: 27318641 [TBL] [Abstract][Full Text] [Related]
8. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Caretti V; Hiddingh L; Lagerweij T; Schellen P; Koken PW; Hulleman E; van Vuurden DG; Vandertop WP; Kaspers GJ; Noske DP; Wurdinger T Mol Cancer Ther; 2013 Feb; 12(2):141-50. PubMed ID: 23270927 [TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237 [TBL] [Abstract][Full Text] [Related]
10. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Russell MR; Levin K; Rader J; Belcastro L; Li Y; Martinez D; Pawel B; Shumway SD; Maris JM; Cole KA Cancer Res; 2013 Jan; 73(2):776-84. PubMed ID: 23135916 [TBL] [Abstract][Full Text] [Related]
11. Not so WEE: targeting G₂/M to kill mesothelioma cells. Dent P Cancer Biol Ther; 2014 Apr; 15(4):351-2. PubMed ID: 24496096 [TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Van Linden AA; Baturin D; Ford JB; Fosmire SP; Gardner L; Korch C; Reigan P; Porter CC Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103 [TBL] [Abstract][Full Text] [Related]
15. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy. Matheson CJ; Casalvieri KA; Backos DS; Reigan P ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531 [TBL] [Abstract][Full Text] [Related]
16. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012 [TBL] [Abstract][Full Text] [Related]
17. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170 [TBL] [Abstract][Full Text] [Related]
18. Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Caiola E; Frapolli R; Tomanelli M; Valerio R; Iezzi A; Garassino MC; Broggini M; Marabese M Sci Rep; 2018 Jan; 8(1):948. PubMed ID: 29343688 [TBL] [Abstract][Full Text] [Related]
19. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Indovina P; Marcelli E; Di Marzo D; Casini N; Forte IM; Giorgi F; Alfano L; Pentimalli F; Giordano A Cancer Biol Ther; 2014 Apr; 15(4):380-8. PubMed ID: 24365782 [TBL] [Abstract][Full Text] [Related]
20. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Bridges KA; Hirai H; Buser CA; Brooks C; Liu H; Buchholz TA; Molkentine JM; Mason KA; Meyn RE Clin Cancer Res; 2011 Sep; 17(17):5638-48. PubMed ID: 21799033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]